Skip to content
  • About the Association
    • Generic Quality
    • About AAM
    • Our Team
    • Our Members
    • Generic Medicines
    • Biosimilars Council
    • Meet Our Board
    • Community Commitment
    • Careers
    • Contact Us
  • About the Association
    • Generic Quality
    • About AAM
    • Our Team
    • Our Members
    • Generic Medicines
    • Biosimilars Council
    • Meet Our Board
    • Community Commitment
    • Careers
    • Contact Us
  • Resources
    • 2025 Savings Report
    • 2025 Advocacy Priorities
    • 2025 First Generics White Paper
    • Drug Shortages White Paper
    • Biosimilars Patient Resource Center
    • Biosimilar Research & Studies
    • Blog
    • Founders Blogs
    • Amicus Briefs
    • Patient Stories
  • Resources
    • 2025 Savings Report
    • 2025 Advocacy Priorities
    • 2025 First Generics White Paper
    • Drug Shortages White Paper
    • Biosimilars Patient Resource Center
    • Biosimilar Research & Studies
    • Blog
    • Founders Blogs
    • Amicus Briefs
    • Patient Stories
  • Advocacy
    • Federal Advocacy
    • Biosimilars
    • GDUFA/BsUFA User Fees
    • Inflation Reduction Act
    • Intellectual Property & Patent Reform
    • Medicaid Generics Penalty
    • State Advocacy
    • Tariffs & Trade
  • Events
    • GRx+Biosims 2025
    • Access! 2026
  • Press Releases
  • JOIN
  • Advocacy
    • Federal Advocacy
    • Biosimilars
    • GDUFA/BsUFA User Fees
    • Inflation Reduction Act
    • Intellectual Property & Patent Reform
    • Medicaid Generics Penalty
    • State Advocacy
    • Tariffs & Trade
  • Events
    • GRx+Biosims 2025
    • Access! 2026
  • Press Releases
  • JOIN
Search Icon
SideMenu
Home
Fact Sheet

Biosimilars Council Press Releases

Fact Sheet

  • Fact Sheet
  • February 28, 2023
  • AAM

AAM Opposes HF17 and SF168 Which Won’t Bring Down Drug Prices for Minnesota Patients

  • Fact Sheet
  • October 13, 2022
  • AAM

How to Talk to Voters About the High Cost of Medicines and Ways to Lower Them

  • Fact Sheet
  • June 8, 2022
  • AAM

The Hatch-Waxman 180-Day Exclusivity Incentive Accelerates Patient Access to First Generics

  • Fact Sheet
  • April 26, 2022
  • AAM

Veto Illinois HB 1780 Which Puts Patient Access to Generic Medicines at Risk

  • Fact Sheet
  • February 4, 2022
  • AAM

Cancer Patients Save $16 Billion Per Year with Generics and Biosimilars

  • Fact Sheet
  • January 31, 2022
  • AAM

GDUFA Reauthorization: A Primer

  • Fact Sheet
  • January 31, 2022
  • AAM

BsUFA Reauthorization: A Primer

  • Fact Sheet
  • January 31, 2022
  • AAM

The Generic Drug User Fee Amendments (GDUFA III)

  • Fact Sheet
  • January 13, 2022
  • AAM

Generics and Biosimilar Medicines Deliver More Savings Every Year

  • Fact Sheet
  • March 31, 2021
  • AAM

Oppose Oregon SB 764

  • Fact Sheet
  • January 14, 2021
  • AAM

AAM Issue Brief: Biosimilars Medicare Part B

  • Fact Sheet
  • December 15, 2020
  • AAM

Letter from AAM: Mr. President, Block the BLOCKING Act!

Load More
Association for Accessible Medicines
601 New Jersey Ave NW, Suite 850
Washington DC 20001
  • 202.249.7100
  • info@accessiblemeds.org
JOIN

Advocacy

  • Federal Advocacy
  • Biosimilars
  • GDUFA/BsUFA User Fees
  • Intellectual Property & Patent Reform
  • Inflation Reduction Act
  • Medicaid Generics Penalty
  • State Advocacy
  • Tariffs & Trade
  • Press Releases
  • Stay Informed

About Us

  • Generic Quality
  • Our Team
  • Our Members
  • Generic Medicines
  • Biosimilars Council
  • Meet Our Board
  • Community Commitment
  • Careers
  • Contact Us

Events

  • GRx+Biosims 2025
  • Access! 2026

Resources

  • 2024 Savings Report
  • Drug Shortages
White Paper
  • Biosimilars Patient
Resource Center
  • Biosimilars Research &
Studies
  • Blog
  • Founders Blogs
  • Amicus Briefs
  • Patient Stories

Sign-up for Update

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Subscribe

© 2025 Association for Accessible Medicines (AAM), All Rights Reserved
Privacy Policy  |  Terms of Use  |  Contact

Stay Connected

For the latest updates, follow us on social media.

Facebook-f X-twitter Linkedin-in Youtube Instagram
  • Resources
    • 2025 Savings Report
    • 2025 Advocacy Priorities
    • 2025 First Generics White Paper
    • Drug Shortages White Paper
    • Biosimilars Patient Resource Center
    • Biosimilar Research & Studies
    • Blog
    • Founders Blogs
    • Amicus Briefs
    • Patient Stories
  • About the Association
    • Generic Quality
    • About AAM
    • Our Team
    • Our Members
    • Generic Medicines
    • Biosimilars Council
    • Meet Our Board
    • Community Commitment
    • Careers
    • Contact Us
  • Advocacy
    • Federal Advocacy
    • Biosimilars
    • GDUFA/BsUFA User Fees
    • Inflation Reduction Act
    • Intellectual Property & Patent Reform
    • Medicaid Generics Penalty
    • State Advocacy
    • Tariffs & Trade
  • Events
    • GRx+Biosims 2025
    • Access! 2026
  • Press Releases
  • JOIN
  • About the Association
    • Generic Quality
    • About AAM
    • Our Team
    • Our Members
    • Generic Medicines
    • Biosimilars Council
    • Meet Our Board
    • Community Commitment
    • Careers
    • Contact Us
  • Resources
    • 2025 Savings Report
    • 2025 Advocacy Priorities
    • 2025 First Generics White Paper
    • Drug Shortages White Paper
    • Biosimilars Patient Resource Center
    • Biosimilar Research & Studies
    • Blog
    • Founders Blogs
    • Amicus Briefs
    • Patient Stories
  • Advocacy
    • Federal Advocacy
    • Biosimilars
    • GDUFA/BsUFA User Fees
    • Inflation Reduction Act
    • Intellectual Property & Patent Reform
    • Medicaid Generics Penalty
    • State Advocacy
    • Tariffs & Trade
  • Events
    • GRx+Biosims 2025
    • Access! 2026
  • Press Releases
  • JOIN